Company Encyclopedia
View More
name
TIANDA PHARMA
00455.HK
Tianda Pharmaceuticals Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. It operates through the Chinese Medicine, Pharmaceuticals and Medical Technologies, and Medical and Healthcare Services segments. The company offers Chinese herbal medicine, Chinese medicine decoction pieces, Chinese medicine products, and Chinese medicine clinical services. It also produces pharmaceutical products focusing on cardiovascular and cerebrovascular chronic diseases, respiratory infections, and pediatric diseases.
1.466 T
00455.HKMarket value -Rank by Market Cap -/-

Financial Score

07/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking43/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-13.08%D
    • Profit Margin-21.70%E
    • Gross Margin41.41%B
  • Growth ScoreE
    • Revenue YoY-19.28%E
    • Net Profit YoY-42.54%D
    • Total Assets YoY-3.72%D
    • Net Assets YoY-10.82%D
  • Cash ScoreE
    • Cash Flow Margin-460.87%E
    • OCF YoY-19.28%E
  • Operating ScoreC
    • Turnover0.39C
  • Debt ScoreB
    • Gearing Ratio37.34%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TIANDA PHARMA: Zhu Haomiao appointed as non-executive director

    According to the Zhitong Finance APP, TIANDA PHARMA announced that Mr. Feng Quanming has resigned as a non-executive director of the company due to other work arrangements, effective from August 29, 2025. Mr. Zhu Haomiao has been appointed as a non-executive director, effective from August 29, 2025

    Zhitong·
    HK
    00455
    0.00%
    Zhitong·
    HK
    00455
    0.00%

    TIANDA PHARMA released its interim results, with a loss attributable to shareholders of HKD 33.237 million, an increase of 22.03% year-on-year

    According to the Zhitong Finance APP, TIANDA PHARMA released its mid-term results for 2025, reporting revenue of HKD 137 million, a year-on-year decrease of 12.45%; the loss attributable to shareholders of the company was HKD 33.237 million, a year-on-year increase of 22.03%; basic loss per share was HKD 1.55

    Zhitong·
    HK
    00455
    0.00%
    Zhitong·
    HK
    00455
    0.00%

    TIANDA PHARMA: Xian Yanfang appointed as a member of the Nomination Committee

    According to the announcement from TIANDA PHARMA, starting from June 27, 2025: Independent non-executive director Zhao Chongkang will no longer serve as a member of the company's nomination committee; independent non-executive director Xian Yanfang has been appointed as a member of the nomination committee; and independent non-executive director Lin Rihui has been appointed as the chief independent non-executive director. The chief independent non-executive director is not an executive position in the company and does not hold any management position in the group

    Zhitong·
    HK
    00455
    0.00%
    Zhitong·
    HK
    00455
    0.00%

    TIANDA PHARMA announced its 2024 performance, with a loss attributable to shareholders of HKD 61.371 million, an increase of 1.54 times year-on-year

    TIANDA PHARMA announced its 2024 performance, with revenue of approximately HKD 330 million, a year-on-year decrease of 37.99%; the loss attributable to shareholders was HKD 61.371 million, a year-on-year increase of 1.54 times, with a loss per share of HKD 0.0285. Revenue from the pharmaceuticals and medical technology business was HKD 283.9 million, down 39.7%. Revenue from traditional Chinese medicine business fell to HKD 27.1 million due to intense market competition. Revenue from medical and healthcare services increased to HKD 19 million

    Zhitong·
    HK
    00455
    0.00%
    Zhitong·
    HK
    00455
    0.00%

    TIANDA PHARMA issues profit warning, expects annual loss attributable to shareholders of no less than HKD 61 million

    TIANDA PHARMA issued a profit warning, expecting an annual loss attributable to shareholders of no less than HKD 61 million for the year ending December 31, 2024, a significant increase from HKD 24.2 million in the same period of 2023. The main reasons for the increase in losses include a revenue decline of approximately 38% and a provision for goodwill impairment of HKD 1.3 million, the latter being non-recurring and non-cash in nature, which does not affect cash flow

    Zhitong·
    HK
    00455
    0.00%
    Zhitong·
    HK
    00455
    0.00%
    © 2025 Longbridge｜Disclaimer